Sunday, September 24, 2023
  • English
  • Marathi
No Result
View All Result
Daily PRABHAT
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
    • Health
    • Lifestyle
    • Technology
    • Science
Daily PRABHAT
No Result
View All Result
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
Home Health

Researchers identify unique genetic variants to overcome cancer treatment barriers

by Digital Desk
2 years ago
in Health, Science
A A
Researchers identify unique genetic variants to overcome cancer treatment barriers
Share on FacebookShare on Twitter

Washington : University of California, Los Angeles researchers add monoclonal antibody to target oropharyngeal cancer in HPV-positive patients with KRAS gene variant.

This research represents current and future efforts to identify patients uniquely sensitive to innovative targeted treatments.

The research builds on studies led by Dr Joanne Weidhaas at UCLA Jonsson Comprehensive Cancer Center, who found that about 16 per cent of head and neck cancer patients have inherited a variant KRAS gene. When these patients receive standard chemoradiation treatments for their HPV-positive squamous cell cancers of the oropharynx, they have both worse toxicity and worse rates of cancer control, Chin said. However, these poor outcomes may be reversed with the addition of a short course of cetuximab.

“In standard clinical practice, tumours are assumed to be different, but patients mostly uniform,” Chin said. “Thus, we spent a lot of energy analysing tumours. However, we have since come to understand that our body’s own immune system is crucial in making treatments effective. Matching the right body to the right treatment may make our treatments less toxic and more effective.”

Chin said UCLA researchers are conducting a clinical trial in which patients with this unique combination – having both the KRAS-variant and HPV-positive squamous cell oropharyngeal cancer – are randomised to either standard of care treatment or standard of care plus cetuximab. “We think this approach of identifying unique clusters of patients may be a way for us to design new treatments that are more personalised and effective,” he said.

Tags: cancercancer treatmentgenetic variantshealthhealth and lifestyleHPV-positivetreatment
ShareTweetSendShareSend

Latest News

“What makes BJP leaders talk in this manner…”: Salman Khurshid on Bidhuri’s communal slurs

Uttarakhand: Police starts crackdown on drug peddlers under “Drug Free Devbhoomi 2025” campaign

“This shows BJP practices politics of hatred”: Adhir Ranjan Chowdhury on communal slurs by Ramesh Bidhuri

UAE, Indonesia reviewing strengthening economic cooperation

EAM Jaishankar, Cambodia PM hold meeting on sidelines of UNGA session 

“Women’s empowerment is inseparable part of Indian culture”: Rajnath Singh on passage of Nari Shakti Vandan Adhiniyam 

Neither Sonia Gandhi nor Mallikarjun Kharge spoke a word: Biplab Kumar Deb on Udai Bhan’s remarks

Rahul Gandhi rides pillion on girl student’s scooter in Jaipur

Ghaziabad: Girl dies after two-storey building collapses in Loni; police suspect cylinder blast

Chinese court sentences Uyghur folklorist Rahile Dawut to life imprisonment: Report 

Washington : University of California, Los Angeles researchers add monoclonal antibody to target oropharyngeal cancer in HPV-positive patients with KRAS gene variant. This research represents current and future efforts to identify patients uniquely sensitive to innovative targeted treatments. The research builds on studies led by Dr Joanne Weidhaas at UCLA Jonsson Comprehensive Cancer Center, who found that about 16 per cent of head and neck cancer patients have inherited a variant KRAS gene. When these patients receive standard chemoradiation treatments for their HPV-positive squamous cell cancers of the oropharynx, they have both worse toxicity and worse rates of cancer control, Chin said. However, these poor outcomes may be reversed with the addition of a short course of cetuximab. "In standard clinical practice, tumours are assumed to be different, but patients mostly uniform," Chin said. "Thus, we spent a lot of energy analysing tumours. However, we have since come to understand that our body's own immune system is crucial in making treatments effective. Matching the right body to the right treatment may make our treatments less toxic and more effective." Chin said UCLA researchers are conducting a clinical trial in which patients with this unique combination - having both the KRAS-variant and HPV-positive squamous cell oropharyngeal cancer - are randomised to either standard of care treatment or standard of care plus cetuximab. "We think this approach of identifying unique clusters of patients may be a way for us to design new treatments that are more personalised and effective," he said.
No Result
View All Result
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
    • Health
    • Lifestyle
    • Technology
    • Science